We found that the path from central obesity and T2DM was adversely mediated by adiponectin, suggesting that elevating adiponectin secretion may be the therapeutic potentials for protecting obesity from T2DM. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.